Dose-effect meta-analysis for psychopharmacological interventions using randomised data.

Hamza, Tasnim; Furukawa, Toshi A; Orsini, Nicola; Cipriani, Andrea; Salanti, Georgia (2022). Dose-effect meta-analysis for psychopharmacological interventions using randomised data. Evidence-Based Mental Health, 25(1), pp. 1-6. BMJ Publishing Group 10.1136/ebmental-2021-300278

	Text Hamza_EvidBasedMentHealth_2022.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (889kB) | Request a copy
Preview	Text Hamza_EvidBasedMentHealth_2022_AAM.pdf - Accepted Version Available under License Publisher holds Copyright. Download (461kB) | Preview
Preview	Text Hamza_EvidBasedMentHealth_2022_supplmat.pdf - Supplemental Material Available under License Publisher holds Copyright. Download (442kB) | Preview

OBJECTIVE

The current practice in meta-analysis of the effects of psychopharmacological interventions ignors the administered dose or restricts the analysis in a dose range. This may introduce unnecessary uncertainty and heterogeneity. Methods have been developed to integrate the dose-effect models in meta-analysis.

METHODS

We describe the two-stage and the one-stage models to conduct a dose-effect meta-analysis using common or random effects methods. We illustrate the methods on a dataset of selective serotonin reuptake inhibitor antidepressants. The dataset comprises 60 randomised controlled trials. The dose-effect is measured on an odds ratio scale and is modelled using restricted cubic splines to detect departure from linearity.

RESULTS

The estimated summary curve indicates that the probability of response increases up to 30 mg/day of fluoxetine-equivalent which results in reaching 50% probability to respond. Beyond 40 mg/day, no further increase in the response is observed. The one-stage model includes all studies, resulting in slightly less uncertainty than the two-stage model where only part of the data is analysed.

CONCLUSIONS

The dose-effect meta-analysis enables clinicians to understand how the effect of a drug changes as a function of its dose. Such analysis should be conducted in practice using the one-stage model that incorporates evidence from all available studies.

Interest & Impact

Downloads

11 since deposited on 28 Jan 2022
8 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item